Literature DB >> 7707082

N-acetylaspartate and N-acetylaspartylglutamate levels in Alzheimer's disease post-mortem brain tissue.

D Jaarsma1, L Veenma-van der Duin, J Korf.   

Abstract

The tissue concentrations of two related amino acid derivatives, N-acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) were determined in autopsy hippocampus, amygdala, cerebellar cortex and olfactory bulb of Alzheimer's disease patients and age-matched non-demented controls, using reverse-phase HPLC and fluorescence detection after precolumn derivatisation with the fluorophore 2-aminoanthracene. In Alzheimer's disease, NAA and NAAG concentrations were significantly reduced in the hippocampus (by 38 and 24%) and the amygdala (by 28 and 22%), but not in the olfactory bulb and the cerebellar cortex. These results indicate that the concentrations of NAA and NAAG are selectively decreased in brain areas affected by pathology in Alzheimer's disease.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7707082     DOI： 10.1016/0022-510x(94)90077-9

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN： 0022-510X            Impact factor:   3.181


  10 in total

1.  Neurometabolites and associations with cognitive deficits in mild cognitive impairment: a magnetic resonance spectroscopy study at 7 Tesla.

Authors:  Georg Oeltzschner; S Andrea Wijtenburg; Mark Mikkelsen; Richard A E Edden; Peter B Barker; Jin Hui Joo; Jeannie-Marie S Leoutsakos; Laura M Rowland; Clifford I Workman; Gwenn S Smith
Journal:  Neurobiol Aging       Date:  2018-09-27       Impact factor: 4.673

2.  Magnetization transfer imaging and proton MR spectroscopy in the evaluation of axonal injury: correlation with clinical outcome after traumatic brain injury.

Authors:  G Sinson; L J Bagley; K M Cecil; M Torchia; J C McGowan; R E Lenkinski; T K McIntosh; R I Grossman
Journal:  AJNR Am J Neuroradiol       Date:  2001-01       Impact factor: 3.825

3.  Contingent vulnerability of entorhinal parvalbumin-containing neurons in Alzheimer's disease.

Authors:  A Solodkin; S D Veldhuizen; G W Van Hoesen
Journal:  J Neurosci       Date:  1996-05-15       Impact factor: 6.167

4.  Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.

Authors:  Kristen A Rahn; Crystal C Watkins; Jesse Alt; Rana Rais; Marigo Stathis; Inna Grishkan; Ciprian M Crainiceau; Martin G Pomper; Camilo Rojas; Mikhail V Pletnikov; Peter A Calabresi; Jason Brandt; Peter B Barker; Barbara S Slusher; Adam I Kaplin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-19       Impact factor: 11.205

5.  Inhibition of glutamate-carboxypeptidase-II in dorsolateral prefrontal cortex: potential therapeutic target for neuroinflammatory cognitive disorders.

Authors:  Shengtao Yang; Dibyadeep Datta; Alvaro Duque; Yury M Morozov; Jon Arellano; Barbara S Slusher; Min Wang; Amy F T Arnsten
Journal:  Mol Psychiatry       Date:  2022-06-22       Impact factor: 13.437

6.  Unbiased Metabolomic Investigation of Alzheimer's Disease Brain Points to Dysregulation of Mitochondrial Aspartate Metabolism.

Authors:  Giuseppe Paglia; Matteo Stocchero; Stefano Cacciatore; Steven Lai; Peggi Angel; Mohammad Tauqeer Alam; Markus Keller; Markus Ralser; Giuseppe Astarita
Journal:  J Proteome Res       Date:  2016-01-12       Impact factor: 4.466

7.  Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology.

Authors:  David J Braun; David K Powell; Christopher J McLouth; Saktimayee M Roy; D Martin Watterson; Linda J Van Eldik
Journal:  PLoS One       Date:  2022-01-26       Impact factor: 3.752

8.  Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis.

Authors:  Kristen R Hollinger; Anjali Sharma; Carolyn Tallon; Lyndah Lovell; Ajit G Thomas; Xiaolei Zhu; Robyn Wiseman; Ying Wu; Siva P Kambhampati; Kevin Liaw; Rishi Sharma; Camilo Rojas; Rana Rais; Sujatha Kannan; Rangaramanujam M Kannan; Barbara S Slusher
Journal:  Nanotheranostics       Date:  2022-01-01

Review 9.  N-Acetyl-Aspartyl-Glutamate in Brain Health and Disease.

Authors:  Cecilie Morland; Kaja Nordengen
Journal:  Int J Mol Sci       Date:  2022-01-23       Impact factor: 5.923

10.  Human Gray and White Matter Metabolomics to Differentiate APOE and Stage Dependent Changes in Alzheimer's Disease.

Authors:  Tyler C Hammond; Xin Xing; Lucy M Yanckello; Arnold Stromberg; Ya-Hsuan Chang; Peter T Nelson; Ai-Ling Lin
Journal:  J Cell Immunol       Date:  2021
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.